Global Pulmonary Drugs Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period.
Pulmonary drugs are the medications which are indicated for the treatment of several types of pulmonary disease such as asthma, pneumonia, allergic rhinitis, pulmonary hypertension, and others.
The global pulmonary drug market is primarily driven by increasing incidence of chronic respiratory diseases, tobacco smoking, and government & non-government initiatives. Other factors like the increase in disposable income, rise in investments for R&D, and increasing healthcare spending are opportunities driving the global pulmonary drugs market. Also, the entrance of innovative and effective drugs in the pulmonary drugs market and substantial investments in the emerging of respiratory drug delivery systems is expected to drive the future of the market.
On the other hand, the availability of counterfeit drugs, patent expiry of drugs, and increasing manufactures of generic medicines in the pulmonary drugs market might hamper the growth.
Based on the drug classes, the combination drugs segment holds the largest market share as it is comparatively nontoxic than the other drugs and key companies face no competition from generic alternatives. Additionally, the emergence of advanced and inexpensive drug delivery systems and the advent of triple combination drugs are expected to stimulate the market segment throughout the forecast period.
Region-wise, North America has the dominant share in the global pulmonary drugs market and can be attributed to the growing number of respiratory diseases in the region. According to the Centers for Disease Control and Prevention (CDC), 2018, the number of adults aged 18 and over who currently have asthma in the U.S. are 19.10 million.
Also, the Asia-Pacific region is expected to be the fastest-growing market throughout the forecast period, thanks to the rapidly improving healthcare infrastructure and the presence of a broad base of the target population. The rise of disposable income and their growing expenditure on healthcare boost the pulmonary drug market in the Asia Pacific region.
The report covers recent development of the market for pulmonary drugs such as January 2019, the U.S. Food and Drug Administration approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older in patients with COPD.
The objective of the report is to present comprehensive analysis of global pulmonary drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report also helps in understanding global pulmonary drugs market dynamics, structure by analyzing the market segments, and project the global pulmonary drugs market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global pulmonary drugs market make the report investor’s guide.
for more information visit:https://www.maximizemarketresearch.com/market-report/global-pulmonary-drugs-market/37939/
Scope of the Global Pulmonary Drugs Market
Global Pulmonary Drugs Market, By Drug Class
• Inhaled Corticosteroids (ICS)
• Long-Acting Beta2-Agonists (LABA)
• Antihistamines
• Vasodilators
• Short-Acting Beta2-Agonists (SABA)
• Anticholinergics
• Combination Drugs
• Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
Global Pulmonary Drugs Market, By Application
• Asthma & COPD
• Allergic Rhinitis
• Pulmonary Arterial Hypertension
• Cystic Fibrosis
• Others
Global Pulmonary Drugs Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• E-commerce
Global Pulmonary Drugs Market, By Region
• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South America
Key players operating in Global Pulmonary Drugs Market
• Sunovion Pharmaceuticals Inc.
• AstraZeneca
• Novartis AG
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc.
• Teva Pharmaceutical Industries Ltd.
• Merck Sharp & Dohme Corp
• Boehringer Ingelheim International GmbH.
• Actelion Pharmaceuticals Ltd
• Bayer AG
• Sanofi SA
• Meda Pharmaceuticals
• Circassia Pharmaceuticals Plc.
• Mallinckrodt Pharmaceuticals Plc.
• Cheisi Farmaceutici S.p.A
• Zambon Company S.p.A
• Alaxia SAS
This Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info:
Name: Lumawant Godage
Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.
Email: sales@maximizemarketresearch.com
Address : Pune, Maharashtra 411051, India.
Contact: +919607195908
